ADMA Biologics Q1 earnings exceeded expectations by 60%, with a 43.9% YoY revenue increase and a stock price rise to $8.96.
ADMA Biologics, a biotech company specializing in plasma-derived biologics, reported Q1 earnings of $0.08 per share, exceeding analyst expectations of $0.05 by $0.03. Revenue reached $81.9 million, a 43.9% year-over-year increase. ADMA updated its 2024 and 2025 guidance for earnings per share. The company's stock price rose $2.03 on Friday, reaching $8.96, with a consensus rating of "Buy" and an average price target of $10.50.
May 10, 2024
7 Articles